These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 22381116)
1. The discovery of novel β-secretase inhibitors: pharmacophore modeling, virtual screening, and docking studies. Niu Y; Ma C; Jin H; Xu F; Gao H; Liu P; Li Y; Wang C; Yang G; Xu P Chem Biol Drug Des; 2012 Jun; 79(6):972-80. PubMed ID: 22381116 [TBL] [Abstract][Full Text] [Related]
2. Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay. Xu W; Chen G; Liew OW; Zuo Z; Jiang H; Zhu W Bioorg Med Chem Lett; 2009 Jun; 19(12):3188-92. PubMed ID: 19447035 [TBL] [Abstract][Full Text] [Related]
3. In silico multi-filter screening approaches for developing novel beta-secretase inhibitors. Fujimoto T; Matsushita Y; Gouda H; Yamaotsu N; Hirono S Bioorg Med Chem Lett; 2008 May; 18(9):2771-5. PubMed ID: 18434150 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase. Palakurti R; Vadrevu R Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181 [TBL] [Abstract][Full Text] [Related]
6. In silico discovery of beta-secretase inhibitors. Huang D; Lüthi U; Kolb P; Cecchini M; Barberis A; Caflisch A J Am Chem Soc; 2006 Apr; 128(16):5436-43. PubMed ID: 16620115 [TBL] [Abstract][Full Text] [Related]
7. BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides. Bertini S; Ghilardi E; Asso V; Granchi C; Minutolo F; Pineschi M; Di Bussolo V; Bortolato A; Moro S; Saba A; Macchia M Bioorg Med Chem; 2010 Nov; 18(22):7991-6. PubMed ID: 20934348 [TBL] [Abstract][Full Text] [Related]
8. Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease. Monenschein H; Horne DB; Bartberger MD; Hitchcock SA; Nguyen TT; Patel VF; Pennington LD; Zhong W Bioorg Med Chem Lett; 2012 Jun; 22(11):3607-11. PubMed ID: 22572583 [TBL] [Abstract][Full Text] [Related]
9. Impact of ligand protonation on virtual screening against beta-secretase (BACE1). Polgar T; Magyar C; Simon I; Keserü GM J Chem Inf Model; 2007; 47(6):2366-73. PubMed ID: 17944457 [TBL] [Abstract][Full Text] [Related]
10. Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening. Xu W; Chen G; Zhu W; Zuo Z Bioorg Med Chem Lett; 2010 Oct; 20(19):5763-6. PubMed ID: 20732815 [TBL] [Abstract][Full Text] [Related]
11. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. Polgár T; Keserü GM J Med Chem; 2005 Jun; 48(11):3749-55. PubMed ID: 15916426 [TBL] [Abstract][Full Text] [Related]
12. Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors. Vijayan RS; Prabu M; Mascarenhas NM; Ghoshal N J Chem Inf Model; 2009 Mar; 49(3):647-57. PubMed ID: 19434899 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel inhibitors of dipeptidylcarboxypeptidase of Leishmania donovani via ligand-based virtual screening and biological evaluation. Gangwar S; Baig MS; Shah P; Biswas S; Batra S; Siddiqi MI; Goyal N Chem Biol Drug Des; 2012 Feb; 79(2):149-56. PubMed ID: 22014034 [TBL] [Abstract][Full Text] [Related]
14. On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches. Huang D; Gu Q; Ge H; Ye J; Salam NK; Hagler A; Chen H; Xu J J Chem Inf Model; 2012 May; 52(5):1356-66. PubMed ID: 22545675 [TBL] [Abstract][Full Text] [Related]
15. Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors. Coimbra JRM; Baptista SJ; Dinis TCP; Silva MMC; Moreira PI; Santos AE; Salvador JAR Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32244832 [TBL] [Abstract][Full Text] [Related]
16. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study. Chakraborty S; Kumar S; Basu S Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237 [TBL] [Abstract][Full Text] [Related]
17. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Zuo Z; Luo X; Zhu W; Shen J; Shen X; Jiang H; Chen K Bioorg Med Chem; 2005 Mar; 13(6):2121-31. PubMed ID: 15727865 [TBL] [Abstract][Full Text] [Related]
18. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Gupta S; Fallarero A; Järvinen P; Karlsson D; Johnson MS; Vuorela PM; Mohan CG Bioorg Med Chem Lett; 2011 Feb; 21(4):1105-12. PubMed ID: 21273074 [TBL] [Abstract][Full Text] [Related]
19. BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296. Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G Bioorg Med Chem Lett; 2010 Aug; 20(15):4639-44. PubMed ID: 20579874 [TBL] [Abstract][Full Text] [Related]
20. In silico screening of drugs to find potential gamma-secretase inhibitors using pharmacophore modeling, QSAR and molecular docking studies. Raman AE; Krishnan K; Maurya A; Sarkar N Comb Chem High Throughput Screen; 2014; 17(9):770-80. PubMed ID: 25329837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]